Gilead Sciences Inc NASDAQ:GILD Price, Chart, News & Insight

Gilead Sciences (GILD) Shares Climb After HSBC Sets $155 Price Target

Gilead Sciences (NASDAQ: GILD) gained 4.2% on Thursday and added another 1.3% in premarket trading on Monday after HSBC initiated coverage on the biopharmaceutical company with a *$155 price target*.

The new price target came as Gilead shares extended their recent rally, reflecting continued investor optimism toward the company's growth prospects across its HIV, oncology, and liver disease portfolios.

The $155 target implies additional upside from Thursday's closing price, suggesting HSBC sees room for further appreciation despite the stock's recent gains. While the rating summary did not disclose the firm's detailed investment thesis, the initiation highlights growing institutional interest in Gilead.

Investor sentiment has also been supported by the company's diversified portfolio, strong cash generation, and continued investment in innovative therapies. Gilead remains focused on expanding its oncology business while maintaining its leadership position in HIV treatments, two areas viewed as key long-term growth drivers.

The combination of Thursday's strong rally and HSBC's new price target kept Gilead in focus as investors continued to favor large-cap pharmaceutical companies with stable earnings and attractive growth opportunities.

💬 🔗

European Investor 07-06-26

# Gilead Edges Lower After Hours as Acquisition Charges Swamp Strong Operating Quarter

Foster City, May 7, 2026 — Shares in Gilead Sciences slipped roughly 1% in after-hours trading yesterday after the biopharmaceutical company reported a solid first quarter operationally but issued full-year EPS guidance that alarmed investors at first glance — a dramatic reduction driven almost entirely by the accounting cost of three major acquisitions rather than any deterioration in the underlying business.

The operating results were genuinely strong. Total revenues grew 4% to $7.0 billion, with base business product sales excluding Veklury up 8% to $6.8 billion. HIV remains the engine, with HIV product sales growing 10% to $5.0 billion. Biktarvy, the company's flagship HIV treatment, rose 7% to $3.4 billion, and Descovy surged 38% to $807 million. Trodelvy, the oncology antibody-drug conjugate, grew 37% to $402 million, reflecting strengthening demand. Non-GAAP diluted EPS improved to $2.03 from $1.81 a year ago, and product gross margin expanded to 87.5% on a non-GAAP basis. Full-year product sales guidance was raised to $30.0 to $30.4 billion from the prior range.

The jolt came from the updated EPS guidance. Full-year non-GAAP diluted EPS was cut to a loss of $0.65 to $1.05, compared to prior guidance of $8.45 to $8.85 — a swing of roughly $9.50 per share. The reason is entirely attributable to $11.5 billion in anticipated acquired in-process R&D charges from the company's acquisition spree: the completed $7.8 billion purchase of Arcellx, the pending acquisition of Ouro Medicines for autoimmune treatments, and the pending Tubulis deal for next-generation antibody-drug conjugates. These are non-cash accounting charges that hit the income statement at closing but represent strategic investments in future pipeline assets rather than operational losses.

Investors familiar with biotech acquisition accounting will recognize the pattern, but the headline EPS reversal is jarring enough to explain the modest after-hours dip as others digest what is actually a strong underlying quarter.

💬 🔗

WS Investor 05-08-26

Gilead Sciences announced it has completed its acquisition of Arcellx Inc. in a deal valued at approximately $7.8 billion, strengthening its oncology portfolio.

The transaction gives Gilead full control of anitocabtagene autoleucel (anito-cel), an investigational CAR T-cell therapy for multiple myeloma, allowing the company to streamline development and maximize long-term value by eliminating profit-sharing and royalty obligations.

Gilead said the deal is expected to be dilutive to earnings in 2026 and 2027 but accretive from 2028 onward, subject to regulatory approval of the therapy. Arcellx will now operate as a wholly owned subsidiary of Gilead.

Source: Gilead Sciences press release, Business Wire

💬 🔗

The Investor 04-28-26

Gilead Sciences to Release First Quarter 2026 Financial Results on Thursday, May 7, 2026

💬 🔗

The Investor 04-24-26

Gilead Sciences announced that it has secured all required regulatory approvals for its acquisition of Arcellx, clearing a key hurdle toward completing the transaction.

The approval process concluded after clearance from the Australian Competition and Consumer Commission, with the final waiting period set to expire on April 27, 2026. The company also confirmed that other international regulatory reviews have been completed, meaning all approval conditions will be satisfied once the waiting period ends.

Gilead has extended its tender offer for Arcellx shares to April 27, maintaining the offer at $115 per share in cash plus a contingent value right tied to future sales milestones of its lead therapy. As of mid-April, approximately 17.5% of shares had been tendered.

The deal remains subject to customary closing conditions, including majority shareholder participation, but positions Gilead to strengthen its oncology pipeline and expand its capabilities in cell therapy as it moves closer to completing the acquisition.
Business Wire

💬 🔗

European Investor 04-18-26

Gilead Sciences Inc. announced expanded global investment in its HIV prevention drug lenacapavir, with support from PEPFAR and The Global Fund to increase access in high-risk, low-resource regions.

The additional commitment aims to provide lenacapavir to up to 1 million more people over the next three years, bringing the total target to 3 million individuals by 2028. The twice-yearly injectable treatment is considered a major breakthrough in HIV prevention and is already being distributed in regions such as sub-Saharan Africa.

Gilead stated it will supply the drug at no profit to these global health programs in the near term, while preparing for a broader rollout through generic manufacturing starting in 2027. The initiative is supported by partnerships with multiple generic drug producers to expand long-term affordability and accessibility.

The move comes as global health organizations continue efforts to reduce the approximately 1.3 million new HIV infections each year, with long-acting prevention therapies seen as a key tool in combating the epidemic.
Business Wire

💬 🔗

WS Investor 04-14-26

Gilead Sciences, Inc. announced it will acquire Tubulis GmbH in a deal valued at up to $5 billion, strengthening its oncology pipeline.

The transaction includes $3.15 billion in upfront cash and up to $1.85 billion in milestone payments. Tubulis brings a next-generation antibody-drug conjugate (ADC) platform and clinical-stage assets, including TUB-040, currently in development for ovarian and lung cancers.

Gilead said the acquisition will enhance its capabilities in targeted cancer therapies by adding advanced ADC technologies designed to improve drug delivery and treatment outcomes.

The deal is expected to close in the second quarter of 2026, subject to regulatory approvals, with Tubulis to operate as a dedicated research unit within Gilead.
Business Wire

💬 🔗

WS Investor 04-07-26

Gilead Sciences announced it has extended its tender offer to acquire Arcellx, pushing the deadline to April 24, 2026.

The offer remains at $115 per share in cash plus a contingent value right (CVR) that could provide an additional $5 per share if future sales milestones are met. As of March 31, about 7.5% of Arcellx shares had been tendered.

The acquisition is expected to close in the second quarter of 2026, subject to regulatory approvals and other customary conditions, including majority shareholder participation.

Gilead said the extension allows additional time for shareholders to participate as it continues efforts to complete the transaction and strengthen its oncology pipeline.
Business Wire

💬 🔗

Global Finance News 04-03-26

Galapagos NV has entered into a binding agreement with Gilead Sciences to collaborate on advancing a first-in-class T cell engager program for autoimmune diseases, centered on the drug candidate gamgertamig.

The agreement is linked to Gilead’s planned $1.675 billion acquisition of Ouro Medicines, with additional milestone payments of up to $500 million. Under the deal, Galapagos will fund 50% of the upfront and milestone costs while gaining access to key intellectual property and operational assets, including Ouro’s research platform.

Gamgertamig, currently in Phase 1/2 studies, has shown strong early efficacy and safety in severe autoimmune conditions such as autoimmune hemolytic anemia and immune thrombocytopenia, and could enter late-stage trials as early as 2027.

The collaboration also provides Galapagos with greater financial flexibility, including control over at least $500 million in cash for independent strategic initiatives and potential shareholder returns. Gilead will lead global commercialization, paying tiered royalties to Galapagos upon market launch.

The companies said the partnership aims to accelerate development of innovative immune therapies targeting high unmet medical needs.

💬 🔗

The Investor 03-31-26

Gilead Sciences, Inc. announced a definitive agreement to acquire Arcellx, Inc. for $115 per share in cash plus a $5 contingent value right, representing an implied equity value of $7.8 billion.

The deal gives Gilead full control of anitocabtagene autoleucel (anito-cel), an investigational BCMA-directed CAR T-cell therapy for relapsed or refractory multiple myeloma. The FDA has accepted the biologics license application, with a PDUFA action date of December 23, 2026. Gilead expects the transaction to accelerate development and commercialization while eliminating profit-sharing, milestone payments and royalties.

The transaction is anticipated to close in the second quarter of 2026, subject to regulatory approvals and tender conditions, and is expected to be accretive to earnings per share in 2028 and thereafter.

Source: Business Wire

💬 🔗

The Investor 02-23-26

NASDAQ:GILDFollow

NASDAQ:GILD